Safety and immunogenicity of human papillomavirus vaccination in juvenile patients with rheumatic diseases

Heijstek, MW; Groot, Noortje; Scherpenisse, Mirte; Tacke, Carline E.; Berbers, Guy A. M.; Klis, Fiona van der; Wulffraat, NM

doi:10.1186/1546-0096-9-s1-o41

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibody concentrations were similar in 68 JIA patients including 9 on TNFα-inhibitors compared to controls after the third vaccination in one study ( 15 ). However, lower antibody concentrations were found in another study with 21 JIA patients including 6 on TNFα-inhibitors, in 6 jSLE patients and 6 JDM patients ( 17 , 50 ).…”

Section: Resultsmentioning

confidence: 74%

“…Some studies investigated multiple vaccines ( Table 1 ). The studies covered the non-live vaccines against Diphtheria Tetanus Polio (DTP, 6 studies), Hepatitis A virus (HAV, 4 studies), Hepatitis B virus (HBV, 7 studies), Human Papillomavirus (HPV, 4 studies), Influenza (13 studies), Meningococcus C (1 study) and Pneumococci (both the pneumococcal conjugate vaccination (PCV) and/or the 23-valent pneumococcal polysaccharide vaccine (PPSV-23) vaccine, 6 studies) ( 9 – 50 ). In addition, studies were included that reported on the live-attenuated vaccines against Measles, Mumps and Rubella (MMR, 12 studies, including 3 on the combined MMR-Varicella booster) ( 12 – 14 , 51 – 59 ), Varicella Zoster Virus (VZV, 5 studies) ( 59 – 63 ), one study which included 1 patient with oral polio vaccine ( 59 ) and one case report on the Bacillus Calmette-Guérin (BCG) vaccine ( 64 ).…”

Section: Resultsmentioning

confidence: 99%

“…Since 2011, 4 cohort studies were performed including 109 patients (89 JIA, 14 jSLE, 6 JDM) and 125 healthy controls that assessed the HPV vaccine ( 15 – 17 , 50 ). Efficacy was not assessed, all studies evaluated antibody titers as surrogate endpoint.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy, Immunogenicity and Safety of Vaccination in Pediatric Patients With Autoimmune Inflammatory Rheumatic Diseases (pedAIIRD): A Systematic Literature Review for the 2021 Update of the EULAR/PRES Recommendations

et al. 2022

View full text Add to dashboard Cite

BackgroundIn 2011, the first European League Against Rheumatism (EULAR) vaccination recommendations for pediatric patients with autoimmune inflammatory rheumatic diseases (pedAIIRD) were published. The past decade numerous new studies were performed to assess the safety, efficacy and immunogenicity of vaccinations in pedAIIRD. A systematic literature review (SLR) was therefore performed to serve as the basis for the updated 2021 EULAR/PRES recommendations.MethodsAn SLR was performed according to the standard operating procedures for EULAR-endorsed recommendations. Primary outcomes were efficacy, immunogenicity and safety of vaccination in pedAIIRD. The search was performed in Medline, Embase and the Cochrane Library and included studies published from November 2010 until July 2020.ResultsThe SLR yielded 57 studies which were included for critical appraisal and data extraction. Only 8 studies described the occurrence of vaccine-preventable infections after vaccination (efficacy), none of these studies were powered to assess efficacy. The majority of studies assessed (humoral) immune responses as surrogate endpoint for vaccine efficacy. Studies on non-live vaccines showed that these were safe and in general immunogenic. Biologic disease-modifying antirheumatic drugs (bDMARDs) in general did not significantly reduce seroprotection rates, except for B-cell depleting therapies which severely hampered humoral responses. Four new studies on human papilloma virus vaccination showed that this vaccine was safe and immunogenic in pedAIIRD. Regarding live-attenuated vaccinations, level 1 evidence of the measles mumps rubella (MMR) booster vaccination became available which showed the safety of this booster for patients treated with methotrexate. In addition, level 3 evidence became available that suggested that the MMR and varicella zoster virus (VZV) vaccination for patients on low dose glucocorticosteroids and bDMARDs might be safe as well.ConclusionsThe past decade, knowledge on the safety and immunogenicity of (live-attenuated) vaccines in pedAIIRD significantly increased. Data on efficacy (infection prevention) remains scarce. The results from this SLR are the basis for the updated EULAR/PRES vaccination recommendations in pedAIIRD.

show abstract

Section: Resultsmentioning

confidence: 74%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy, Immunogenicity and Safety of Vaccination in Pediatric Patients With Autoimmune Inflammatory Rheumatic Diseases (pedAIIRD): A Systematic Literature Review for the 2021 Update of the EULAR/PRES Recommendations

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Since 2011, 4 cohort studies were performed including 109 patients (89 JIA, 14 jSLE, 6 JDM) and 125 healthy controls that assessed the HPV vaccine (15)(16)(17)50). Efficacy was not assessed, all studies evaluated antibody titers as surrogate endpoint.…”

Section: Human Papilloma Virus Vaccine Efficacy-immunogenicity-safetymentioning

confidence: 99%

Table_1.DOCX

View full text Add to dashboard Cite

Section: Human Papilloma Virus Vaccine Efficacy-immunogenicity-safetymentioning

confidence: 99%

Table_2.DOCX

View full text Add to dashboard Cite

Safety and immunogenicity of human papillomavirus vaccination in juvenile patients with rheumatic diseases

Cited by 4 publications

References 0 publications

Efficacy, Immunogenicity and Safety of Vaccination in Pediatric Patients With Autoimmune Inflammatory Rheumatic Diseases (pedAIIRD): A Systematic Literature Review for the 2021 Update of the EULAR/PRES Recommendations

Efficacy, Immunogenicity and Safety of Vaccination in Pediatric Patients With Autoimmune Inflammatory Rheumatic Diseases (pedAIIRD): A Systematic Literature Review for the 2021 Update of the EULAR/PRES Recommendations

Table_1.DOCX

Table_2.DOCX

Contact Info

Product

Resources

About